Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Axorus logo — Contact Lens to restore sight in dry Age-related Macular Deg...

Axorus

Contact Lens to restore sight in dry Age-related Macular Degeneration (dry AMD) or Retinitis Pigmentosa (RP).

Founded 2019 France France 4 employees Seed Total: $1.20M Medical Devices

General Information

Company Name Axorus
Founded Year 2019
Location France France
Founders / Decision Makers
Team member
Employees 4
Industries Medical Devices
Funding Stage Seed
Business Model B2C, D2C, B2B
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Axorus. To contact Axorus, visit axorus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Axorus compare?

A PDF of Axorus and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Axorus soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Axorus

Axorus, founded in 2019 and headquartered in France, is making strides in the Medical Devices industry with its innovative approach to ophthalmic technology. The company is focused on developing a novel Contact Lens designed to restore sight in individuals suffering from vision impairments such as dry Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP).

As a startup dedicating its efforts to address significant vision health challenges, Axorus has already captured the attention of the investor community, securing a substantial €368.00K Seed Round investment on 17 July 2020. This funding round was led by key investors including Nord France Amorcage, Finovam Gestion, and Happy Capital, showcasing strong confidence in the company's potential to impact the healthcare sector.

Overall, Axorus stands out as a promising venture poised to redefine treatment options for patients with degenerative eye diseases, offering a promising investment opportunity in the burgeoning field of medical technology.

Business keywords: Contact Lens Innovation, Sight Restoration Technology, Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Artificial Retina Development, Photoacoustic Neurostimulation, Boston University Collaboration, Vision Restoration, Biotech Startup, Medical Technology, Ophthalmology Solutions, Precision Neurostimulation, Biomedical Engineering

Services & Products

Development of contact lenses using photoacoustic technology
Vision restoration devices for retinal diseases
Non-invasive retinal stimulation

Target Customers

Patients with dry AMD Patients with Retinitis Pigmentosa Healthcare providers in ophthalmology Vision specialists

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed €370.00K 3
Nord France Amorcage Finovam Gestion Happy Capital
Nord France Amorcage, Finovam Gestion +1
01 Jul 2020
Spinout €830.00K 2
Nord France Amorcage Finovam Gestion
Nord France Amorcage, Finovam Gestion
01 Oct 2019
Support Program Undisclosed 1
Santé Ventures
Santé Ventures
01 Feb 2019

Axorus Alternatives & Competitors

View All Alternatives
Axorus vs
LumiThera, Inc.
LumiThera, Inc. United States

Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin...

Venture round
34 employees
Health Care, Manufacturing
Axorus vs
CELLiCO
CELLiCO Korea South

Innovative health & medical device manufacturing company improving human life

Seed
6 employees
Fashion, Health Care
Axorus vs
Johnson & Johnson | Vision
Johnson & Johnson | Vision United States

As J&J MedTech, a leader in eye health, we are paving the way for a new future of vision care at eve...

Series D
5449 employees
Health Care, Medical Devices
View all alternatives

FAQ About Axorus

Contact Lens to restore sight in dry Age-related Macular Degeneration (dry AMD) or Retinitis Pigmentosa (RP).
Axorus was founded in 2019.
Axorus is headquartered in France.
Axorus operates in Medical Devices. Its work centres on Contact Lens Innovation, Sight Restoration Technology, Dry Age-related Macular Degeneration and Retinitis Pigmentosa. Its customers include Patients with dry AMD, Patients with Retinitis Pigmentosa and Healthcare providers in ophthalmology.
Axorus has a B2C, D2C and B2B business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Axorus has approximately 4 employees.
Axorus has completed 3 funding rounds, raising a total of $1.20M. The latest funding stage is Seed.
Axorus offers: Development of contact lenses using photoacoustic technology, Vision restoration devices for retinal diseases, Non-invasive retinal stimulation.
Top alternatives and competitors to Axorus include LumiThera, Inc., CELLiCO, Johnson & Johnson | Vision, Ocular Therapeutix, Inc., Alcon. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Axorus and LumiThera, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Axorus, https://bouncewatch.com/company/axorus, updated 12 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout